Combination antiretroviral therapy and cell–cell spread of wild-type and drug-resistant human immunodeficiency virus-1

Boghuma Kabisen Titanji,1,2 Deenan Pillay1,3 and Clare Jolly1,*

Abstract

Human immunodeficiency virus-1 (HIV-1) disseminates between T cells either by cell-free infection or by highly efficient direct cell–cell spread. The high local multiplicity that characterizes cell–cell infection causes variability in the effectiveness of antiretroviral drugs applied as single agents. Whereas protease inhibitors (PIs) are effective inhibitors of HIV-1 cell–cell and cell-free infection, some reverse transcriptase inhibitors (RTIs) show reduced potency; however, antiretrovirals are not administered as single agents and are used clinically as combination antiretroviral therapy (cART). Here we explored the efficacy of PI- and RTI-based cART against cell–cell spread of wild-type and drug-resistant HIV-1 strains. Using a quantitative assay to measure cell–cell spread of HIV-1 between T cells, we evaluated the efficacy of different clinically relevant drug combinations. We show that combining PIs and RTIs improves the potency of inhibition of HIV-1 and effectively blocks both cell-free and cell–cell spread. Combining drugs that alone are poor inhibitors of cell–cell spread markedly improves HIV-1 inhibition, demonstrating that clinically relevant combinations of ART can inhibit this mode of HIV-1 spread. Furthermore, comparison of wild-type and drug-resistant viruses reveals that PI- and RTI-resistant viruses have a replicative advantage over wild-type virus when spreading by cell–cell means in the presence of cART, suggesting that in the context of inadequate drug combinations or drug resistance, cell–cell spread could potentially allow for ongoing viral replication.

INTRODUCTION

Over the last three decades, combination antiretroviral therapy (cART) has completely transformed the prognosis of human immunodeficiency virus 1 (HIV-1) infection from a fatal disease to a manageable chronic condition. Despite the success of cART, life-long treatment is limited by cost, development of drug resistance, the need for life-long adherence to therapy and the unknown effects of long-term treatment. In recent years, the focus of HIV-1 research has shifted towards the search for a definitive cure for HIV/AIDS alongside ongoing efforts to develop a vaccine to prevent new infections. These strategies are, however, far from being realized and antiretroviral drugs remain the best weapon to treat and potentially prevent HIV-1 infection. cART leads to a dramatic suppression of viral replication, reducing the plasma levels of circulating HIV-1 RNA copies below levels detectable by conventional clinical assays [1–4]. Despite this considerable success, patients on cART have episodes of intermittent detectable HIV-1 RNA in plasma (blips) [5–7], viral rebound with therapy interruption and can develop antiretroviral drug resistance [4]. Several factors have been hypothesized to explain the inability to completely eradicate HIV-1 using cART, including reduced susceptibility of HIV-1 to cART during cell–cell spread that may contribute to ongoing low-level viral replication [8].

HIV-1 can disseminate between cells either by cell-free fluid phase diffusion of budded viral particles, or by direct cell–cell spread. Cell–cell spread of HIV-1 across a virological synapse (VS) [9] is a highly efficient mode of viral dissemination in comparison to the classical mode of cell-free diffusion [9–14]. This is mainly attributable to the polarized budding of the virus towards the target cell, close physical contact between the effector and target cell, and the clustering of cellular receptors and viral envelope proteins at the interface between the effector cell and the target cell [9, 10, 14, 15]. These factors limit the need for prolonged diffusion and facilitate the efficient transfer of viral particles from the donor cell to the target cell [9, 10, 14, 15]. Numerous studies have demonstrated the reduced susceptibility of cell–cell spread to the effects of some neutralizing antibodies [10, 11, 16–18] and more recently to some classes of antiretroviral drugs [8, 19–22]. Indeed, we and others have shown...
the reduced efficacy of some classes of antiretroviral drugs applied as single agents [8, 19–21]. While protease inhibitors (PIs) remain effective inhibitors of both HIV-1 cell–cell and cell-free infection, some reverse transcriptase inhibitors (RTIs) have significantly reduced potencies against the former mode of infection [19]. These observations seem paradoxical given the strong evidence that cART effectively inhibits viral replication in HIV-1-infected patients [4]. However, conventional first-line cART typically consists of three antiretroviral drugs from at least two different therapeutic classes [4, 23, 24], rather than administration of a single agent. Although two nucleoside RTIs (NRTIs) usually form the backbone of the triple-drug regimen, the third component can be a non-NRTI (NNRTI), a PI or an integrase inhibitor (INI) [23, 24]. Whether clinically relevant drug combinations suppress cell–cell spread of HIV-1 remains unknown, but the matter has clear implications for antiretroviral treatment and eradication strategies.

In the present study, we explore the impact of clinically relevant PI- and RTI-based combinations against cell–cell spread of wild-type and drug-resistant HIV-1 and additionally consider interactions of drugs delivered in combination [25–27]. Our results show that PI- and RTI-based antiretroviral drug combinations effectively inhibit both cell–cell and cell-free spread of HIV-1. Combining drugs that are alone are poor inhibitors of cell–cell spread markedly improves HIV-1 inhibition, demonstrating that clinically relevant drug combinations can suppress HIV-1 replication mediated by highly efficient cell–cell spread. We also report that relatively less fit drug-resistant viruses regain a replicative advantage when spreading by a cell–cell mechanism in the presence of cART, suggesting that in a context of inadequate cART or drug resistance, cell–cell spread may contribute to treatment failure and viral replication.

RESULTS

RTI-based combination therapies effectively inhibit cell–cell and cell-free spread of HIV-1

We and others have previously shown that the RTIs, Tenofovir (TFV), Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP), have significantly reduced potency against HIV-1 cell–cell infection when compared to cell-free infection [8, 19–21]. Importantly, these drugs are not used as monotherapy for the treatment of HIV-1-infected patients, due to the risk of rapidly selecting for drug-resistant variants of the virus. To evaluate the efficacy of clinically relevant drug combinations, we combined different drugs used in cART and measured their activity against HIV-1 cell–cell spread. To do this we took two approaches. Firstly, we simply compared whether drug combinations were able to fully suppress cell–cell spread in vitro. Secondly, we considered whether, when combined, different drug combinations showed improved potency (i.e. synergistic or additive effects) against cell–cell spread. For this, we applied the median effect analysis based on the median effect principle of Chou and Talalay [25–27] to determine the combination index and define whether the interactions between the drugs in the combinations tested were additive, synergistic or antagonistic and compared this between cell–cell and cell-free modes of HIV-1 infection. The median effect analysis is a well-established method for assessing drug interactions and has been applied extensively for evaluating combinations of antiretroviral drugs in drug development studies [28–36].

A well-established quantitative PCR (qPCR) assay for HIV-1 reverse transcripts that directly measures the early steps of HIV-1 infection [10, 19, 37] was used to measure cell–cell and cell-free spread in the presence of RTI-based combinations. This assay was previously used to test the efficacy of PIs and RTIs against HIV-1 cell–cell spread [19]. Having previously validated that Jurkat T cells and primary T cells give similar results when studying cell–cell spread in the presence of ART [19], the Jurkat T cell model system was used here due to the large number of cells needed and the complexity of multiple drug comparisons. Initially, three dual combinations of RTIs – AZT+TFV, TFV+EFV (Efavirenz) and AZT+NVP – were tested. These were chosen as we and others have previously shown that these drugs, when used as single agents, are poor inhibitors of cell–cell spread, compared to PIs for example [8, 19–21]. The drugs were combined in a fixed-dose ratio based on their IC50 values determined in a cell-free infection assay [25–27, 38]. Cell–cell and cell-free spread of wild-type HIV-1 (HIV-1wt) was measured in the presence of a serial dilution of this fixed dose combination. The inhibitory effect (f0) of each drug alone and as part of a combination was calculated and expressed as a fraction, representing inhibition of infection in the presence of the drug relative to the no-drug control. These f0 values were inputted in CompuSyn to determine the combination index (CI) for different concentrations of the drug combination. The mean CI values for 50, 75, 90 and 95 % inhibition levels obtained from two independent experiments and the standard error of the mean are presented.

TFV and AZT, which we have previously shown to be respectively >10- and >20-fold less potent against cell–cell HIV-1 infection, were tested in combination against both cell–cell and cell-free infections. Fig. 1(a) shows that while this combination was able to block both modes of viral spread, more drug was needed to cause equivalent inhibition of cell–cell spread compared to cell-free. CI values showed additive/synergistic effects against cell–cell infection and synergistic effects against cell-free infection (Table 1). AZT and TFV were then respectively combined with non-nucleoside inhibitors NVP and EFV to reflect clinically relevant combinations (Fig. 1b, c). Both AZT and EFV drugs are frequently administered in combination with NRTIs in first-line cART regimens. In our hands, NVP as a single agent has a four-fold reduced potency against cell–cell spread of HIV-1 [19] whereas EFV is equally potent against both cell–cell and cell-free spread of HIV-1, as for PIs [39]. The combination of AZT+NVP inhibited both cell–cell and
cell-free modes of HIV-1 spread with synergistic/additive effects against cell–cell infection and synergistic effects against cell-free infection (Fig. 1b and Table 1). Again, we did observe a slight reduction in efficacy of this drug combination against cell–cell spread compared to cell-free. Notably, TFV+EFV was found to be the most effective combination and potently inhibited both cell-free and cell–cell spread at low concentrations (Fig. 1c). For all the RTI-based combinations tested above, we consistently observed a stronger combined potency of the drugs against cell-free infections compared to cell–cell infections, indicative somewhat of a reduced drug activity during cell–cell spread.

**PI-based combination therapies effectively inhibit cell–cell and cell-free spread of HIV-1**

In contrast to RTIs, PIs are equally effective against both cell–cell and cell-free spread of HIV-1 [19]. The introduction of PIs in the mid-1990s completely revolutionized cART and these drugs are now important components of both first-line and second-line treatment options [4, 23, 24]. We therefore wanted to explore the effects of combining the less effective RTIs with PIs against HIV-1 spread. The PI Lopinavir (LPV) was tested in combination with the NRTI TFV and in combination with the NNRTI NVP. We opted to use LPV as opposed to other PIs because of its position as first-line PI therapy in many resource-limited high-prevalence countries. Both combinations, LPV+TFV and LPV+NVP, potently inhibited cell–cell and cell-free spread of HIV-1 (Fig. 2a, b and Table 1).

**Drug-resistant viruses gain a replicative advantage when spreading cell–cell in the presence of cART**

The development of drug resistance remains one of the biggest challenges of cART. Cell–cell spread of drug-resistant viruses and its possible implications for cART is therefore important. To study the interplay between drug resistance and cell–cell spread of HIV-1 in the context of dual and triple ART combinations, we tested PI and RTI drug-resistant viruses commonly selected by cART in vivo and in vitro. The PI-resistant virus carrying the V82A mutation in

---

**Fig. 1.** RTI-based cART effectively inhibits cell-to-cell and cell-free spread of HIV-1. Cell-to-cell and cell-free infections were assessed in the presence of a serial dilution of dual RTI-based drug combinations: (a) AZT+TFV, (b) AZT+NVP and (c) TFV+EFV. The drugs were combined in ratios based on their IC\textsubscript{50} values determined in a cell-free infection assay. Infection was quantified by detecting HIV-1 pol DNA transcripts generated at each dilution of the combination by qPCR and expressed as a fraction of the no drug control. A representative from two independent experiments is shown. The error bars represent the standard deviation of the mean. The bold lines represent the non-linear regression curve-fit and dotted lines represent actual data points.
protease and the compensatory A431V mutation in Gag (HIV-1dm) is selected for by LPV therapy [40–44] and confers varying degrees of resistance to all PIs except DRV [43, 44]. The NRTI-resistant virus (HIV-1m184v) with M184V in RT is selected for by suboptimal ART containing 3TC or FTC and confers a high level of resistance to these two agents [45, 46]. The NNRTI-resistant virus (HIV-1k103n) with K103N in RT is selected for by NVP or EFV containing ART and confers high levels of resistance to these drugs [47–49]. Besides conferring resistance to the relevant antiretroviral agents, these mutations impose a fitness cost for the replication of these viruses when compared to wild-type HIV in cell-free assays [40, 50, 51].

The drug susceptibility phenotypes of the resistant viruses compared to HIV-1wt were verified in an in-house drug susceptibility assay [41, 52]. As expected, HIV-1dm was susceptible to inhibition by DRV but was 8.4-fold more resistant to inhibition by LPV (Fig. 3a, b). HIV-1m184v was susceptible to inhibition by AZT but was 120-fold more resistant to inhibition by lamivudine (3TC) (Fig. 3c, d). HIV-1k103n was 28-fold more resistant to inhibition by NVP and 650-fold more resistant to inhibition by EFV. After verifying and confirming the phenotype of drug-resistant viruses, the ability of these viruses to spread efficiently by a cell–cell compared to a cell-free mechanism was assessed using the qPCR-based assay system. HIV-1wt cell–cell spread was significantly more efficient

| Mode of infection | Combination index (CI)*† | Effect |
|------------------|--------------------------|--------|
|                  |                          | 50     | 75     | 90     | 95     |
| Cell–cell        | Combination AZT+TFV (ratio=1:1) | 0.9 (0.1) | 0.85 (0.1) | 0.82 (0.05) | 0.74 (0.12) | Additive/synergistic |
| Cell–cell        | AZT+TFV                  | 0.41 (0.06) | 0.39 (0.03) | 0.42 (0.1) | 0.45 (0.04) | Synergistic |
| Cell–cell        | Combination AZT+NVP (ratio=40:1) | 0.95 (0.05) | 1.05 (0.05) | 1.1 (0.13) | 1.1 (0.1) | Additive |
| Cell–free        | AZT+NVP                  | 0.97 (0.06) | 0.89 (0.04) | 0.79 (0.06) | 0.76 (0.1) | Additive/synergistic |
| Cell–cell        | Combination TFV+EFV (ratio=1000:1) | 0.59 (0.05) | 0.46 (0.07) | 0.36 (0.05) | 0.35 (0.02) | Synergistic |
| Cell–free        | TFV+EFV                  | 0.1 (0.02) | 0.13 (0.01) | 0.22 (0.05) | 0.39 (0.1) | Synergistic |
| Cell–cell        | Combination LPV+TFV (ratio=1:1000) | 0.03 (0.06) | 0.1 (0.01) | 0.12 (0.04) | 0.36 (0.2) | Synergistic |
| Cell–free        | LPV+TFV                  | 0.02 (0.01) | 0.06 (0.01) | 0.15 (0.02) | 0.4 (0.13) | Synergistic |
| Cell–cell        | Combination LPV+NVP (ratio=1:25) | 1.1 (0.07) | 0.92 (0.2) | 0.74 (0.24) | 0.71 (0.26) | Additive/synergistic |
| Cell–free        | LPV+NVP                  | 0.86 (0.03) | 0.72 (0.03) | 0.6 (0.04) | 0.46 (0.04) | Additive/synergistic |

*Data are mean and SEM from two independent experiments.
†50, 75, 90 and 95 indicate the percentage inhibition of infection in the presence of the combination being tested.

Fig. 2. PI-based cART effectively inhibits both cell-to-cell and cell-free spread of HIV-1. Cell-to-cell and cell-free infections were assessed in the presence of a serial dilution of a PI+RTI combination: (a) LPV+TFV and (b) LPV+NVP. The drugs were combined in a ratio based on their IC50 values determined in a cell-free infection assay. Infection was quantified by detecting HIV-1 pol DNA transscripts generated at each dilution of the combination by qPCR and expressed as a fraction of the no drug control. A representative from two independent experiments is shown. The error bars represent the standard deviation of the mean. The bold lines represent the non-linear regression curve-fit and dotted lines represent actual data points.
(six-fold) than cell-free spread (Fig. 4a), in agreement with previous reports [10–14, 37, 54]. Similarly, all drug-resistant viruses tested showed more efficient cell–cell spread compared to cell-free spread (Fig. 4b–d). As expected, all drug-resistant viruses maintained their resistant phenotypes when spreading by a cell–cell mechanism and unlike wild-type virus were not inhibited by the presence of the relevant anti-retroviral drug (Fig. 4f–h).

Next, we assessed cell–cell spread of the resistant viruses in the presence of combination therapy. We tested the PI-resistant virus HIV-1dm in the presence of PI-based cART and the RTI-resistant viruses HIV-1k103n and HIV-1m184v in the presence of RTI-based cART. To evaluate the impact of drug resistance on the potency of a given combination, we calculated the CI values for the drug-resistant viruses and compared them to those obtained with the wild-

---

**Fig. 3.** Drug susceptibility of drug-resistant viruses compared to wild-type HIV-1. Drug susceptibility of the drug-resistant viruses was tested in a cell-free-based HeLa TZM-bl drug susceptibility assay. The phenotypes of the viruses were confirmed in this assay and compared to wild-type virus: (a) HIV-1dm was 8.4-fold more resistant to LPV than HIV-1wt but was (b) equally susceptible to DRV as HIV-1wt. (c) HIV-1m184v was as expected susceptible to AZT but was (d) 120-fold more resistant to 3TC than HIV-1wt. (e) HIV-1k103n was 28-fold more resistant to NVP than HIV-1wt, and was (f) 650-fold more resistant to EFV that HIV-1wt. The dotted lines represent actual data points while the bold lines represent the non-linear regression curve fit. The error bars represent the standard deviation of the mean and a representative experiment of two independent repeats is shown.
Drug-resistant viruses spread efficiently by a cell-to-cell mechanism and maintain their resistant phenotype with this mode of spread. Cell-to-cell spread of (a) HIV-1wt, (b) HIV-1dm, (c) HIV-1k103n and (d) HIV-1m184v was measured and compared to their cell-free spread using a qPCR-based cell-to-cell assay system. All viruses spread efficiently by a cell-to-cell mechanism, with this mode of spread being 5–7 times more efficient for all viruses tested in comparison to cell-free spread. (e) Drug-resistant viruses spread from cell to cell with comparable efficiency to wild-type virus. Drug-resistant viruses (f) HIV-1dm, (g) HIV-1k103n and (h) HIV-1m184v all maintain their resistant phenotype when spreading by a cell-to-cell mechanism. A representative of two independent repeats is shown. Error bars show the standard deviation of the mean. Statistical comparisons were done using a paired Student t-test. **** P<0.0001, *** P<0.001, ** P<0.01, ns not significant.
type virus. With the combination of LPV+TFV, HIV-1dm (which is resistant to LPV) had a replicative advantage compared to HIV-1wt when spreading by a cell–cell mechanism (Fig. 5a, b and Table 2), indicating that TFV alone is unable to suppress cell–cell spread, in agreement with previous reports [8, 19–21]. A similar result was obtained for cell–cell spread of HIV-1k103n compared to HIV-1wt in the presence of TFV+EFV, with the resistant virus again showing a distinct replicative advantage over wild-type virus (Fig. 5c, d and Table 2). These results suggest that cell–cell spread of drug-resistant viruses reduces the potency of cART. Combinations that are synergistic against cell–cell spread of wild-type virus become additive or exhibit decreased synergy against cell–cell spread of drug-resistant viruses (Table 2). This observation remained apparent even when TFV+3TC+EFV, a potent clinically relevant first-line triple drug combination, was tested against cell–cell spread of HIV-1k103n (Fig. 5e, f and Table 2).

Finally, cell–cell spread of the NRTI drug-resistant virus HIV-1m184v was tested in the presence of an RTI-based combination and compared to HIV-1wt. The M184V

Fig. 5. Drug-resistant viruses gain a replicative advantage when spreading by a cell-to-cell mechanism in the presence of cART. Cell-to-cell spread of drug-resistant viruses was compared to wild-type virus in the presence of a serial dilution of fixed-dosed PI- and RTI-based drug combinations. Infection was quantified by qPCR detection of HIV-1 pol DNA. HIV-1dm spreads more efficiently by a cell-to-cell mechanism compared to wild-type virus in the presence of LPV+TFV (a, b). HIV-1k103n spreads efficiently by a cell-to-cell mechanism compared to wild-type virus in the presence of TFV+EFV (c, d) and in the presence of TFV+EFV+3TC (e, f). A representative experiment of two independent repeats is shown. The error bars represent the standard deviation of the mean; UT, untreated.
Table 2. CI values against PI-resistant virus (HIV-1<sup>dm</sup>), RTI-resistant virus (HIV-1<sup>k103n</sup>) and wild-type virus during cell-cell spread

| Virus              | Combination index (CI)<sup>†</sup> | Effect          |
|--------------------|-----------------------------------|-----------------|
|                    | 50   | 75   | 90   | 95   |                  |
| HIV-1<sup>wt</sup> | 0.03 (0.06) | 0.1 (0.01) | 0.12 (0.04) | 0.36 (0.2) | Synergistic     |
| HIV-1<sup>dm</sup>| 0.14 (0.01) | 0.21 (0.01) | 0.29 (0.04) | 0.49 (0.1) | Synergistic     |
| HIV-1<sup>1m184v</sup> | 0.69 (0.05) | 0.46 (0.07) | 0.36 (0.05) | 0.35 (0.02) | Synergistic     |
| HIV-1<sup>k103n</sup>| 1.1 (0.02) | 0.93 (0.01) | 0.82 (0.05) | 0.79 (0.1) | Synergistic/additive |
| HIV-1<sup>1m184v</sup> | 0.08 (0.03) | 0.09 (0.01) | 0.12 (0.04) | 0.18 (0.01) | Synergistic     |
| HIV-1<sup>k103n</sup>| 0.35 (0.02) | 0.39 (0.01) | 0.44 (0.02) | 0.48 (0.13) | Synergistic     |

*Data are mean and standard SEM from two independent experiments.
†50, 75, 90 and 95 indicate the percentage inhibition of infection in the presence of the combination being tested.

mutation in RT was particularly interesting for this study because while it confers a 120-fold greater resistance to inhibition by 3TC compared to wild-type virus in the drug susceptibility assay (Fig. 3d), this mutation is also well described for increasing the susceptibility of the virus to other NRTIs, notably TFV and AZT [55–58]. It was therefore of interest to test whether the increased susceptibility of HIV-1m184v to AZT would remain evident when infection was mediated by highly efficient cell–cell spread, not least because cell–cell spread by wild-type HIV-1 is highly impervious to inhibition by AZT [19]. To address this, cell–cell spread of the mutant virus was directly compared to that of the wild-type virus in the presence of AZT. Fig. 6(a) shows that although AZT was unable to fully suppress cell–cell spread of HIV-1<sup>wt</sup>, the drug effectively inhibited cell–cell spread of HIV-1m184v. Cell–cell spread of this resistant mutant was then tested with drug combinations. With the combination of 3TC+AZT, both HIV-1<sup>wt</sup> and HIV-1m184v cell–cell infections were effectively inhibited although HIV-1m184v showed a replication advantage albeit a modest one in the presence of this combination in comparison to HIV-1<sup>wt</sup> (Fig. 6b). The triple RTI combination of 3TC+AZT+EFV potently blocked cell–cell spread of both viruses (Fig. 6c). This finding confirmed the continued efficiency of clinically relevant triple cART in the presence of the M184V mutation.

DISCUSSION

In recent years, the role of HIV-1 cell–cell spread as a means of antiviral escape and a possible mechanism for the maintenance of the viral reservoir has elicited great interest and debate. Our group and others have demonstrated the variable effects of individual antiretroviral drug classes against this mode of infection in vitro [8, 19–21]. However, given the widely accepted and proven efficacy of cART for the treatment of HIV-infected patients, this has been a topic of much discussion.

Here we have assessed the potency of clinically relevant RTI and, for the first time, PI-based drug combinations against cell–cell spread of HIV-1 and compared this to the classical mode of infection by cell-free diffusion. We find cART potently inhibits both cell–cell and cell-free modes of viral dissemination, albeit with a moderately reduced potency against cell–cell infection that is a more efficient means of HIV-1 spread. This is further reflected by weaker observed combined effects (additive or synergistic) of the combinations tested against cell–cell infection, compared to cell-free infection, despite efficient suppression of viral dissemination in vitro. Notably, combining less effective RTIs (AZT+TFV, TFV+EFV, AZT+NVP) and RTIs with potent PIs (LPV+TFV, LPV+NVP) strongly inhibits cell–cell spread. These drug interactions are similar to those observed in previous cell-free-based antiviral drug interaction studies [29–32, 34, 35, 59, 60]. The reduced potency of some antiretroviral drugs against cell–cell spread has been mainly attributed to the high viral m.o.i. that characterizes this mode of dissemination in vitro. Thus it has been suggested that RTIs, which act within target cells, may be more easily saturated by an influx of infectious virions transmitted at the VS, explaining their reduced potency against cell–cell spread in vitro [8, 19, 21]. Our data showing that antiretroviral drugs display enhanced potency when used in combination suggest that cART is probably sufficient to overcome the high multiplicity of cell–cell infections in this in vitro model. Our data are supported by Agosto et al. [21] who evaluated inhibition of HIV-1 cell–cell spread in the presence of RTI combinations using the instantaneous inhibitory potential (IIP) as a parameter to assess the potency and inhibitory capacity of drugs in combination. Like the CI, the IIP is also derived from the median effect equation [25–27, 61, 62]. That two independent studies using different analytical approaches concur that cART can effectively block HIV-1 cell–cell spread addresses the important issue of how cART could control viral replication in vivo, in light of reports attesting to reduced efficacy of single agents against highly efficient cell–cell spread [8, 19–21]. Furthermore,
here we have also included for the first time PIs in cART to evaluate the effect against cell–cell spread, as well as combinations with PIs and NNRTIs. While PIs and NNRTIs are not typically used in cART, that they also demonstrate potency against cell–cell spread further highlights the advantage of combining drugs, even those that alone are poor inhibitors of cell–cell spread, to achieve efficient viral blockade. Taken together, these studies demonstrate that different combinations of cART can effectively block cell–cell spread of HIV-1.

Drug resistance is a major cause of treatment failure, but the interplay between cell–cell infection and cART in the context of resistant virus has been little considered, but has important clinical implications [63, 64]. Our findings that drug-resistant viruses can spread effectively by a cell–cell mechanism in the presence of cART is therefore interesting. The reduced replication fitness of the M184V mutation and its enhanced susceptibility to Tenofovir and Zidovudine has been used as an argument for maintaining patients who select for this resistance mutation on 3TC containing treatment regimens [50, 51, 58, 65]. The rationale is that selecting for and maintaining the relatively unfit M184V virus will translate into a clinical benefit [50, 51, 58, 65]. While this approach appears to work initially, patients eventually fail treatment and still require the replacement of 3TC with alternative second-line options [66]. Here we observed that the NRTI drug-resistant mutant M184V, which has been extensively described in the literature for its diminished replication capacity in cell-free assays [50, 51, 55–57], was capable of cell–cell spread at levels similar to wild-type virus. Indeed, a similar observation has recently been made with the Dolutegravir (DTG)-resistant mutant R263K, which has a diminished capacity to replicate [67] but was found to spread efficiently via cell–cell contacts [68]. In light of our findings, and those of Agosto et al. [21], further testing to elucidate whether cell–cell spread may serve as a means for continued replication and maintenance of ‘unfit’
drug-resistant viruses and analysis of the mechanism involved would be of clear interest.

While it is difficult to extrapolate from in vitro models to explain the complexities of viral replication in vivo, it has been suggested that if cell–cell spread of HIV-1 is taking place in lymphoid tissue in vivo, then this should result in the appearance of cells with multiply-integrated proviruses [54]. Since only a few studies have demonstrated the presence of multiply infected CD4+ lymphocytes in vivo [69, 70], it has been argued that cell–cell spread does not contribute to HIV-1 replication in vivo. However, this may be an over-simplification. Firstly, it is increasingly apparent that the defensive processes associated with high m.o.i. infection induce cellular apoptosis as the result of a high cytoplasmic load of viral DNA [71–73]. This may in turn result in the selection of CD4+ lymphocytes carrying only a single provirus, which are more frequently observed in vivo. Thus these cells may simply be deleted from the pool of cells available for sampling. Secondly, it may not naturally follow that the attachment and entry of multiple viral particles would necessarily result in multiplication units that all lead equally to successful viral integration in the setting of natural spread in vivo. Many aspects of the complex molecular processes that regulate HIV-1 nuclear import and integration remain to be elucidated and future work will undoubtedly shed light on this issue.

Some studies have failed to show evidence of viral evolution in patients receiving fully suppressive cART, arguing against ongoing viral replication in treated patients [74–77]; however, due to the difficulty in sampling niches and sanctuary sites where cell–cell spread probably occurs, these data may not fully capture the true picture. Furthermore, recent data from some raltegravir intensification studies provide support for ongoing viral replication during cART [78–80], although these too are subject to debate (reviewed in [81]). In vivo HIV cell–cell spread would probably occur predominantly in the lymphoid tissues where there is an abundance of CD4+ T cells and effective antiviral drug penetration may be suboptimal [82]. Also, in other anatomical sanctuary sites with reduced drug penetration [82–85], niches of cells in close proximity and the absence of shear flow may favor cell–cell spread. It is reasonable to speculate based on our results that in a context of low adherence to cART, suboptimal drug combinations and drug resistance, cell–cell spread may allow for therapeutic escape due to its enhanced replication efficiency over cell-free spread, even in the presence of cART. The development of improved methods to identify and sample sanctuary sites in HIV-1-infected individuals will help to clarify this issue.

Predicting the outcomes of ART in patients, although highly desirable, remains very difficult in current clinical practice. As new therapies are developed for the treatment of HIV-1, being able to assess the efficacy of novel combinations against all modes of virus dissemination will serve as a valuable tool for predicting their efficacy, prior to clinical testing. In view of our findings, the variable effects of antiretroviral drugs on cell–cell spread of HIV-1 should be considered for future prophylactic, therapeutic and eradication strategies. Employing a simple in vitro assay like the one used for this study provides a straightforward way of doing this.

**METHODS**

**Cells, viruses and inhibitors**

HeLa-TZMBl cells were obtained from the Center for AIDS Reagents, National Institutes of Biological Standard and Control, UK (CFAR, NIBSC) and donated by J. Kappes, X. Wu and Tranzyme Inc. HEK 293T cells were originally from the ATCC (American Type Culture Collection). Adherent cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FCS (Invitrogen), 50 U penicillin ml⁻¹ and 50 µg streptomycin ml⁻¹. The CD4+ CXCR4+ T cell line Jurkat CE6.1 [obtained through AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH (ARRP): from Dr Estuardo Aguilar-Cordova and Dr John Belmont] was maintained in RPMI 1640 supplemented with 10% FCS and 50 U penicillin ml⁻¹ and 50 µg streptomycin ml⁻¹. The HIV-1 clone pNL4.3 was produced by Dr Malcolm Martin and obtained from the ARRP. The antiretroviral drugs Lopinavir (LPV), Nevirapine (NVP), Efavirenz (EFV), Zidovudine (AZT), Lamivudine (3TC) and Tenofivir (TDF) were obtained from the ARRP.

**Construction of drug-resistant viruses**

To construct the drug-resistant variants of NL43, site-directed mutagenesis was performed with Accuprime PfX supermix (Invitrogen) using forward and reverse primers containing the required nucleotide substitutions. For the PI-resistant virus (HIV-1dm) two mutations, V82A, a major protease drug resistance mutation (mutagenesis primers: forward 5¢-GTAGGACCTACAAGATCTCCTGCAACA TAAATTGGAAAG-3¢, reverse 5¢-CGAGTTTCTTCCAATTT GTTGGCAGGTGTAGG-3¢), and A431V, a cleavage site mutation in the p7/p1 junction (mutagenesis primers: forward 5¢-GAAAGATTTGAAGAGACAGGTTAATT GTTTAGG-3¢, reverse 5¢-GGCCAGATCTTTCCCTAAAG TTAACCTGTCTCTCAGT-3¢), were introduced. For the NNRTI-resistant virus (HIVm184v), the M184V mutation was introduced in RT (mutagenesis primers: forward 5¢-GTAGGACCTACAAGATCTCCTGCAACA TAAATTGGAAAG-3¢, reverse 5¢-TATACAGTGGGATGATTTGTATGGATCG ACTG-3¢, reverse 5¢-AATCATCCAGGTAGTAGATGAC TATGTGGATGTTTGG-3¢). For the NNRTI-resistant virus (HIV-k103n), the K103N mutation was introduced in RT (mutagenesis primers: forward 5¢-GTAGGACCTACAAGATCTCCTGCAACA TAAATTGGAAAG-3¢, reverse 5¢-AACAAATCTTACAGGGCTGGGACAAGG-3¢, reverse 5¢-ACAT CAGTAGTGTGTTCTGTTCTGTTAC-3¢). The mutagenesis was carried out in the vector pCR 2.1 TOPO, by sub-cloning a region of HIV-1NL4.3 covering nucleotides 740–2940. Sequencing was performed by BigDye terminator chemistry and a 3730xl analyzer (ABI) to confirm the presence of the mutations introduced and the absence of any other substitutions. The mutated fragment was reintroduced into the HIV-1NL4.3 backbone by SpeI/AgeI.
digested. Stocks of infectious virus (HIV-1dm, HIV-1m184v, HIV-1k103n and HIV-1wt) were made by transfecting 293T cells using FuGene HD (Promega). Infectious viral titres were measured on HeLa-TZMbl reporter cells using the Bright-Glo Luciferase assay kit (Promega).

**Drug susceptibility assay to validate mutagenesis**

An in-house assay was used to determine the drug susceptibility of the mutant drug-resistant viruses compared to the wild-type vector [52, 53]. The assay was modified to accommodate the use of plasmids with full-length HIV-1 genomes. HEK 293T cells were transfected as described above, and 16 h later the cells were seeded in the presence of a serial dilution of PIs. Virus supernatant was harvested 24 h later and used to infect fresh target HeLa-TZMbl cells by spinoculation for 2 h at 1200 g. Replication was determined by measuring luciferase expression in infected target cells at 48 h post-infection using the SteadyGlo luciferase assay system (Promega) and expressed relative to that of no drug controls. Fifty per cent inhibitory concentrations (IC₅₀) were determined using Prism GraphPad Software. The IC₅₀ values calculated are the mean of at least two independent experiments.

**Flow cytometry**

HIV-1-infected Jurkat cells were washed and fixed with 3 % paraformaldehyde (PFA), permeabilized in BD Perm Buffer (BD Biosciences) and stained with anti-HIV p24 monoclonal antibody conjugated to fluorescein isothiocyanate [HIV-1 p24 (24–4) FITC; Santa Cruz Biotechnology] to detect intracellular Gag. Acquisition was performed using a Becton Dickinson FACS Calibur and data were analysed using FlowJo software. Cells were used when >90 % were Gag positive.

**Quantitative real-time PCR assay to measure cell–free and cell–cell spread**

To measure cell–cell transfer from an infected donor cell to an uninfected target cell, real-time PCR was used to detect de novo pol-transcripts as described in previous studies using this assay [10, 19, 37] with modifications to accommodate the use of drug inhibitors (RTIs and PIs). Donor cells were infected at an m.o.i. of 0.3–0.5 with either HIV-1 NL4.3 (wild-type) or drug-resistant mutant virus by spinoculating at 2000 g for 2 h. Three days after infection, the donor cells were stained for Gag and analyzed by flow cytometry. Only donor cell cultures that were >90 % infected were used for experiments. This minimizes the background from spreading infection between donor cells after target cells are added to the culture. In total, 2×10⁵ pre-washed infected Jurkat cells (donors) per well on a 96-well plate were mixed with 8×10⁵ uninfected Jurkat cells (targets) per well in the presence of a serial dilution of the single inhibitor or combination of inhibitors being tested. The co-culture was incubated for 24 h at 37 °C after which the cells were pelleted, stored at −80 °C and genomic DNA was extracted (Qiagen). Quantitative real-time PCR was performed to measure cell–cell spread as described previously using primers and probes specific for HIV-1 pol DNA and the housekeeping gene albumin [10, 19, 37] (HIV-1 pol primers and probe: forward 5'-GCTGGTGAA CGGAGCTGA-3', reverse 5'-ATTCCTAGCCA TTGCCTCAGATT-3', probe 5'-TGAGATTCTCTCA TGTCATCTGGCGCTATCCT-3', albumin primers and probe: forward 5'-CTGGTCATCTATTGCGCTGT-3', reverse 5'-AAACTCATGGAAGCTGTTGTT-3', probe 5'-CTGTCAATGCCCACAAATCTCTCC-3').

Cell-free experiments were performed as previously described [19]. Briefly, pre-washed 2×10⁵ donor cells per well were allowed to produce virus over 24 h. Then, 100 µl of the virus supernatant was used to infect 1×10⁶ target cells per well by spinoinfection at 2000 g for 2 h, in the presence of a serial dilution of the drug combination under investigation. Following infection by spinoinoculation, the target cells were incubated for 24 h, after which they were pelleted for total DNA extraction and subsequent real-time PCR quantification of infection as described previously.

**Drug combination studies**

The real-time PCR-based infection assays described above were used for the drug combination studies. Antiretroviral agents from the RTI and PI classes were tested in clinically relevant combinations. The drugs were combined in a ratio based on the IC₅₀ values of the individual drugs for cell-free infection. For example, if the IC₅₀ of drug A=50 nM and the IC₅₀ of drug B=100 nM, to test these drugs in combination, A+B were combined in a ratio of 1:2 [38]. Cell–cell and cell-free infection was assessed in the presence of a serial dilution of the combination and infection was determined by qPCR as described above. The percentage inhibition at each concentration was determined and expressed as a fraction of the ‘no-drug’ positive control. These values were used to determine the CI values for the drug combination using the drug synergy analysis software CompuSyn (Paramus). The CI obtained can then be interpreted to determine whether the interaction between the drugs under study is synergistic, additive or antagonistic. For the presentation of our data the following cut-offs for CI values according to Chou and Talalay are applied: CI <0.9 = synergy, CI 0.9–1.2 = addition, CI >1.2 = antagonism.

**Funding information**

This work was supported by a Commonwealth Scholarship to B.T.; and a UK Medical Research Council Career Development Fellowship (G0800312) and a Wellcome Trust Investigator Award (108079/Z/15/Z) to C.J. We also acknowledge support from the European Union funded FP7 CHAIN programme (HEALTH-2007.223131), the NIHR UCL Hospitals Biomedical Research Centre and the UCL/MRC Centre for Medical Molecular Virology.

**Acknowledgements**

We thank members of the Pillay and Jolly laboratories for general assistance.

**Conflicts of interest**

The authors declare that there are no conflicts of interest.
References

1. Autran B, Carcelain G, Li TS, Blanc C, Mathez D et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112–116.

2. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM et al. Restoration of Cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:953–956.

3. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS clinical trials group protocol 315. J Infect Dis 1998;178:70–79.

4. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012;2:a007161.

5. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999;282:1627–1632.

6. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000;6:82–85.

7. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000;14:2805–2812.

8. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011;477:95–98.

9. Jolly C, Kashfi K, Holinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004;199:283–293.

10. Martin N, Welsch S, Jolly C, Briggs JA, Vaux D et al. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol 2010;84:3516–3527.

11. Chen P, Hübner W, Spinelli MA, Chen BK. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 2007;81:12582–12595.

12. Mazurov D, Ilinskaya A, Heidecker G, Lloyd P, Derse D. Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathog 2010;6:e1000788.

13. Groot F, Welsch S, Sattentau QJ. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 2008;111:4660–4663.

14. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 2007;81:1000–1012.

15. Jolly C, Welsch S, Michor S, Sattentau QJ. The regulated secretory pathway in CD4+ T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse. PLoS Pathog 2011;7:e1002226.

16. Abela IA, Berlinger L, Schanz M, Reynell L, Günthard HF et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 2012;8:e1002634.

17. Malbec M, Porrot F, Rua H, Horwitz J, Klein F et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med 2013;210:2813–2821.

18. McCoy LE, Groppelli E, Blanchetot C, de Haard H, Verrips T et al. Neutralisation of HIV-1 cell-cell spread by human and llama antibodies. Retrovirology 2014;11:83.

19. Titanji BK, Aasa-Chapman M, Pillay D, Jolly C. Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology 2013;10:161.

20. Duncan CJ, Russell RA, Sattentau QJ. High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. AIDS 2013;27:2201–2206.

21. Agosto LM, Zhong P, Munro J, Mothes W. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Pathog 2014;10:e1003982.

22. Permanyer M, Ballana E, Ruiz A, Badia R, Riveira-Munoz E et al. Antiretroviral agents effectively block HIV replication after cell-to-cell transfer. J Virol 2012;86:8773–8780.

23. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organisation; 2013.

24. DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. USA: NIH; 2014.

25. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.

26. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621–681.

27. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440–446.

28. Deminie CA, Bechtold CM, Stock D, Alam M, Djank F et al. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother 1996;40:1346–1351.

29. Kollmann C, Tremblay C, Gigué F, Chou TC, Hirsch MS. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. Antivir Ther 2001;6:143–144.

30. King RW, Klaber RM, Reid CD, Erickson-Viitanen SK. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother 2002;46:1640–1646.

31. Kulkarni R, Feng JY, Miller MD, White KL. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir. Antiviral Res 2014;101:131–135.

32. Feng JY, Ly JK, Myrick F, Goodman D, White KL et al. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 2009;6:44.

33. Beale KK, Robinson WE Jr. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1. Antiviral Res 2000;46:223–232.

34. Drusano GL, D’Argenio DZ, Symonds W, Biliecco PA, Mcdowell J et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998;42:2153–2159.

35. Gantlett KE, Weber JN, Sattentau QJ. Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res 2007;75:188–197.

36. Schader SM, Colby-Germainino SP, Schachter JR, Xu H, Wainberg MA. Synergy against drug-resistant HIV-1 with the microbicide anti-retrovirals, dapivirine and tenofovir, in combination. AIDS 2011;25:1585–1594.

37. Jolly C, Mital I, Sattentau QJ. Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1. J Virol 2007;81:5547–5560.
38. Irene V, Bijnsdorp V, Peters GJ. Analysis of drug interactions. In: Cree IA (editor). Cancer Cell Culture: Methods and Protocols. 2nd ed. New York: Springer Science; 2011.
39. Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D et al. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 2007;368:60–72.
40. Luca AD. The impact of resistance on viral fitness and its clinical implications. In: Geretti AM (editor). Antiretroviral Drug Resistance in Clinical Practice. London, UK: Mediscrpt; 2006.
41. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997;71:6667–6670.
42. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005;2:e112.
43. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004;350:1023–1035.
44. Dam E, Quercia R, Glass B, Descamps D, Launay O et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 2009;5:e1000345.
45. Eron JJ, Benoit SL, Jemsek J, Macarthur RD, Santana J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV working party. N Engl J Med 1995;333:1662–1669.
46. Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM (editor). Antiretroviral Resistance in Clinical Practice. London, UK: Mediscrpt; 2006.
47. Bachelor LT, Anton ED, Kudish P, Baker D, Bunville J et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44:2475–2484.
48. Bachelor L, Jeffrey S, Hanna G, D’Aquilla R, Wallace L et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008.
49. de Béthune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res 2010;85:75–90.
50. Cong ME, Heneine W, Garcia-Lemma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007;81:3037–3041.
51. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN et al. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 2009;83:2038–2043.
52. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D et al. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS 2010;24:1651–1655.
53. Parry CM, Kolli M, Myers RE, Cane PA, Schiffer C et al. Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob Agents Chemother 2011;55:1106–1113.
54. Del Portallo A, Tripodi J, Najfeld V, Wodarz D, Levy DN et al. Multiploid inheritance of HIV-1 during cell-to-cell infection. J Virol 2011;85:7169–7176.
55. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antiviral Ther 2001;6:115–126.
56. White KL, Margot NA, Win T, Petropoulos CJ, Miller MD et al. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002;46:3437–3446.
57. Diallo K, Gütt E, Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2003;47:3377–3383.
58. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003;47:3478–3484.
59. Borrot–Esoda K, Velà JE, Myrick F, Ray AS, Miller MD. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and entecavir. Antiviral Ther 2006;11:371–384.
60. Chaouananthan T, Krogstad E, Ball C, Woodrow KA. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One 2013;8:e61416.
61. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008;14:762–766.
62. Shen L, Rabi SA, Siliciano RF. A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci 2009;30:610–616.
63. Agosto LM, Uchil PD, Mothes W. HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy. Trends Microbiol 2015;23:289–295.
64. Casartelli N. Human immunodeficiency virus-1 cell-to-cell transmission and antiviral strategies: an overview. Curr Drug Targets 2015.
65. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005;41:236–242.
66. Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J et al. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antiviral Ther 2012;17:81–770.
67. Mespède T, Wainberg MA. Is resistance to dolagavir possible when this drug is used in first-line therapy? Viruses 2014;6:3377–3385.
68. Bastarache SM, Mespède T, Donahue DA, Sloan RD, Wainberg MA. Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency. Viruses 2014;6:3487–3499.
69. Gratton S, Cheynier N, Dumaurier MJ, Oksenhendler E, Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad Sci USA 2000;97:14566–14571.
70. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V et al. Recombination: multiply infected spleen cells in HIV patients. Nature 2002;418:144.
71. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM et al. Cell death by pyroptosis drives CD4 T-cell deletion in HIV-1 infection. Nature 2014;505:509–514.
72. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abnormally infected with HIV. Science 2014;343:428–432.
73. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA et al. HIV-1 causes C64 cell death through DNA-dependent protein kinase during viral integration. Nature 2013;498:376–379.
74. Kieffer TL,Finucane MM, Nettles RE, Quinn TC, Broman KW et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004;189:1452–1465.
75. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of variant clones rarely found in circulating CD4+ T cells. J Virol 2006;80:6441–6457.
76. Evering TH, Mehandru S, Rac P, Tenner-Racz K, Poles MA et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 2012;8:e1002506.

77. Josefsson L, von Stockenstrom S, Faria NR, Sinclair E, Bacchetti P et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Nat Acad Sci USA 2013;110:E987–96.

78. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010;16:460–465.

79. Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 2012;17:355–364.

80. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infectious Dis 2013;208:1436–1442.

81. Shan L, Siliciano RF. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays 2013;35:544–552.

82. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Nat Acad Sci USA 2014;111:2307–2312.

83. Cu-Uvin S, Delong AK, Venkatesh KK, Hogan JW, Ingersoll J et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010;24:2489–2497.

84. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010;329:174–180.

85. Deleage C, Moreau M, Rioux-Leclercq N, Ruffault A, Jégou B et al. Human immunodeficiency virus infects human seminal vesicles in vitro and in vivo. Am J Pathol 2011;179:2397–2408.

---

**Five reasons to publish your next article with a Microbiology Society journal**

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.